- Home
- NVAX vs CVAC Comparison
NVAX vs CVAC Comparison
Compare NVAX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- CVAC
- Stock Information
- Founded
- NVAX 1987
- CVAC 2000
- Country
- NVAX United States
- CVAC Germany
- Employees
- NVAX N/A
- CVAC N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- NVAX Health Care
- CVAC Health Care
- Exchange
- NVAX Nasdaq
- CVAC Nasdaq
- Market Cap
- NVAX 1.3B
- CVAC 1.2B
- IPO Year
- NVAX 1995
- CVAC 2020
- Fundamental
- Price
- NVAX $7.98
- CVAC $5.33
- Analyst Decision
- NVAX Buy
- CVAC Hold
- Analyst Count
- NVAX 7
- CVAC 3
- Target Price
- NVAX $14.29
- CVAC $6.83
- AVG Volume (30 Days)
- NVAX 7.2M
- CVAC 501.6K
- Earning Date
- NVAX 11-11-2025
- CVAC 11-11-2025
- Dividend Yield
- NVAX N/A
- CVAC N/A
- EPS Growth
- NVAX N/A
- CVAC N/A
- EPS
- NVAX 2.54
- CVAC 1.01
- Revenue
- NVAX $1,078,718,000.00
- CVAC $599,540,810.00
- Revenue This Year
- NVAX $61.69
- CVAC N/A
- Revenue Next Year
- NVAX N/A
- CVAC $24.04
- P/E Ratio
- NVAX $3.25
- CVAC $5.36
- Revenue Growth
- NVAX 9.22
- CVAC 675.15
- 52 Week Low
- NVAX $5.01
- CVAC $2.37
- 52 Week High
- NVAX $15.22
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- NVAX 51.06
- CVAC 40.53
- Support Level
- NVAX $7.63
- CVAC $5.33
- Resistance Level
- NVAX $8.31
- CVAC $5.41
- Average True Range (ATR)
- NVAX 0.35
- CVAC 0.04
- MACD
- NVAX -0.00
- CVAC -0.01
- Stochastic Oscillator
- NVAX 65.20
- CVAC 3.85
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.